Joseph P. Nathan, PharmD, MS

GLP-1 receptor agonists show promise in alleviating depressive symptoms in patients with type 2 diabetes, offering a potential dual benefit in treatment.

Historically, colchicine has been used primarily in the management of gout; however, in 2023, the FDA approved Lodoco, a newly marketed colchicine product, for the management of cardiovascular disease.

Despite its importance, after graduating from pharmacy school, many pharmacists likely experience a decline in confidence in their ability to appropriately evaluate studies and interpret statistical findings.

Patients with MDD may also seek complementary or alternative therapies in the form of dietary supplements which might be perceived by patients to be natural and safer than medicinal agents.

Because decongestants act by constricting blood vessels, their use can be problematic in individuals who have hypertension.

With generic prescriptions on the rise, every pharmacist needs a through understanding of therapeutic equivalence and the generic approval process.